Therapeutic potential of orphan drugs for the rare skeletal muscle diseases

Bibliography

• Myshko D. Rare diseases: Research, development, and commercialization. PharmaVOICE, PharmaLinx LLC 2015;15-24
   Google Scholar
• Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy 2015;119:964-79
   PubMed Web of Science ®Google Scholar
• Anastasi G, Amato A, Tarone G, et al. Distribution and localization of vinculin-talin-integrin system and dystrophin-glycoprotein complex in human skeletal muscle. Immunohistochemical study using confocal laser scanning microscopy. Cells Tissues Organs 2003;175:151-64
   PubMed Web of Science ®Google Scholar
• Peter AK, Cheng H, Ross RS, et al. The costamere bridges sarcomeres to the sarcolemma in striated muscle. Prog Pediatr Cardiol 2011;31:83-8
   PubMedGoogle Scholar
• Ramaswamy KS, Palmer ML, van der Meulen JH, et al. Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats. J Physiol 2011;589:1195-208
   PubMed Web of Science ®Google Scholar
• Lorson CL, Hahnen E, Androphy EJ, et al. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 1999;96:6307-11
   PubMed Web of Science ®Google Scholar
• Taylor JE, Thomas NH, Lewis CM, et al. Correlation of SMNt and SMNc gene copy number with age of onset and survival in spinal muscular atrophy. Eur J Hum Genet 1998;6:467-74
   PubMed Web of Science ®Google Scholar
• Schrank B, Gotz R, Gunnersen JM, et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci USA 1997;94:9920-5
   PubMed Web of Science ®Google Scholar
• Cobb MS, Rose FF, Rindt H, et al. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy. Hum Mol Genet 2013;22:1843-55
   PubMed Web of Science ®Google Scholar
• Bebee TW, Dominguez CE, Chandler DS. Mouse models of SMA: tools for disease characterization and therapeutic development. Hum Genet 2012;131:1277-93
   PubMed Web of Science ®Google Scholar
• Khademian H, Mehravar E, Urtizberea J, et al. Prevalence of GNE p.M712T and hereditary inclusion body myopathy (HIBM) in Sangesar population of Northern Iran. Clin Genet 2013;84:589-92
   PubMed Web of Science ®Google Scholar
• Broccolini A, Mirabella M. Hereditary inclusion-body myopathies. Biochim Biophys Acta 2015;1852:644-50
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Beckemeyer AA. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond. Pediatr Endocrinol Rev 2014;12(Suppl 1):114-24
   PubMedGoogle Scholar
• Hoffman EP, Connor EM. Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies. Discov Med 2013;16:233-9
   PubMed Web of Science ®Google Scholar
• Pistilli EE, Bogdanovich S, Goncalves MD, et al. Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am J Pathol 2011;178:1287-97
   PubMed Web of Science ®Google Scholar
• Morine KJ, Bish LT, Selsby JT, et al. Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy. Muscle Nerve 2010;42:722-30
   PubMed Web of Science ®Google Scholar
• Murphy KT, Ryall JG, Snell SM, et al. Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice. Am J Pathol 2010;176:2425-34
   PubMed Web of Science ®Google Scholar
• Nakatani M, Takehara Y, Sugino H, et al. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J 2008;22:477-87
   PubMed Web of Science ®Google Scholar
• Parsons SA, Millay DP, Sargent MA, et al. Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol 2006;168:1975-85
   PubMed Web of Science ®Google Scholar
• Bogdanovich S, Krag TO, Barton ER, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002;420:418-21
   PubMed Web of Science ®Google Scholar
• Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther 2015;23:192-201
   PubMed Web of Science ®Google Scholar
• Haidet AM, Rizo L, Handy C, et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci USA 2008;105:4318-22
   PubMed Web of Science ®Google Scholar
• Kota J, Handy CR, Haidet AM, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med 2009;1:6ra15
   PubMed Web of Science ®Google Scholar
• Milo biotechnology announces FDA orphan drug designation. Milo Biotechnology Press release. 2012. Available from: http://milobiotechnology.com/2012/12/12/milo-biotechnology-announces-fda-orphan-drug-designation/ [Last accessed 23 June 2015]
   Google Scholar
• Rodino-Klapac LR, Janssen PM, Shontz KM, et al. Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model. Hum Mol Genet 2013;22:4929-37
   PubMed Web of Science ®Google Scholar
• First Duchenne muscular dystrophy patient treated in Follistatin gene therapy trial. Milo Biotechnology Press release. 2015. Available from: http://milobiotechnology.com/2015/04/09/first-duchenne-muscular-dystrophy-patient-treated-in-follistatin-gene-therapy-trial/ [Last accessed 15 May 2015]
   Google Scholar
• Murphy KT, Chee A, Gleeson BG, et al. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am J Physiol Regul Integr Comp Physiol 2011;301:R716-26
   PubMed Web of Science ®Google Scholar
• Murphy KT, Cobani V, Ryall JG, et al. Acute antibody-directed myostatin inhibition attenuates disuse muscle atrophy and weakness in mice. J Appl Physiol 1985 2011;110:1065-72
   Google Scholar
• Murphy KT, Koopman R, Naim T, et al. Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. FASEB J 2010;24:4433-42
   PubMed Web of Science ®Google Scholar
• Krivickas LS, Walsh R and Amato AA. Single muscle fiber contractile properties in adults with muscular dystrophy treated with MYO-029. Muscle Nerve 2009;39:3-9
   PubMed Web of Science ®Google Scholar
• Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008;63:561-71
   PubMed Web of Science ®Google Scholar
• Attie KM, Borgstein NG, Yang Y, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve 2013;47:416-23
   PubMed Web of Science ®Google Scholar
• Acceleron and Shire Conclude Collaboration on ACE-031. Acceleron Pharma Press release. 2013. Available from: http://investor.acceleronpharma.com/releasedetail.cfm?ReleaseID=785701 [Last accessed 24 June 2015]
   Google Scholar
• Acuna MJ, Pessina P, Olguin H, et al. Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-beta signalling. Hum Mol Genet 2014;23:1237-49
   PubMed Web of Science ®Google Scholar
• Mulivor A, Cannell M, Davies M, et al. ACE-083, a ligand trap for members of the TGF-b superfamily, increases muscle mass locally in a mouse model of Duchenne muscular dystrophy. 19th International congress of the world muscle society. Berlin, Germany. October 9, 2014
   Google Scholar
• Murphy KT, Allen AM, Chee A, et al. Disruption of muscle renin-angiotensin system in AT1a-/- mice enhances muscle function despite reducing muscle mass but compromises repair after injury. Am J Physiol Regul Integr Comp Physiol 2012;303:R321-31
   PubMed Web of Science ®Google Scholar
• Marangoni RA, Carmona AK, Passaglia RC, et al. Role of the kallikrein-kinin system in Ang-(1-7)-induced vasodilation in mesenteric arterioles of Wistar rats studied in vivo-in situ. Peptides 2006;27:1770-5
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Trask AJ and Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 2005;289:H2281-90
   PubMed Web of Science ®Google Scholar
• Tallant EA, Ferrario CM and Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 2005;289:H1560-6
   PubMed Web of Science ®Google Scholar
• Iwata M, Cowling RT, Gurantz D, et al. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 2005;289:H2356-63
   PubMed Web of Science ®Google Scholar
• Grobe JL, Mecca AP, Lingis M, et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 2007;292:H736-42
   PubMed Web of Science ®Google Scholar
• Benter IF, Diz DI and Ferrario CM. Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7). Hypertension 1995;26:1138-44
   PubMed Web of Science ®Google Scholar
• Benter IF, Ferrario CM, Morris M, et al. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol 1995;269:H313-19
   PubMed Web of Science ®Google Scholar
• Ferreira AJ, Santos RA, Almeida AP. Angiotensin-(1-7):cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 2001;38:665-8
   PubMed Web of Science ®Google Scholar
• Sabharwal R, Cicha MZ, Sinisterra RD, et al. Chronic oral administration of Ang-(1-7) improves skeletal muscle, autonomic and locomotor phenotypes in muscular dystrophy. Clin Sci (Lond) 2014;127:101-9
   PubMed Web of Science ®Google Scholar
• TXA127 for the treatment of muscular dystrophies. Franklin R. TACT (TREAT-NMD advisory committee for therapeutics). 2014. Available from: www.treat-nmd.eu/resources/tact/reviews/past/txa127/ [Last accessed 23 June 2015]
   Google Scholar
• Colussi C, Mozzetta C, Gurtner A, et al. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA 2008;105:19183-7
   PubMed Web of Science ®Google Scholar
• Minetti GC, Colussi C, Adami R, et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 2006;12:1147-50
   PubMed Web of Science ®Google Scholar
• Vianello S, Consolaro F, Bich C, et al. Low doses of arginine butyrate derivatives improve dystrophic phenotype and restore membrane integrity in DMD models. FASEB J 2014;28:2603-19
   PubMed Web of Science ®Google Scholar
• Leoni F, Fossati G, Lewis EC, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005;11:1-15
   PubMed Web of Science ®Google Scholar
• Consalvi S, Mozzetta C, Bettica P, et al. Preclinical studies in the mdx mouse model of Duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. Mol Med 2013;19:79-87
   PubMed Web of Science ®Google Scholar
• Parent project muscular dystrophy to collaborate with Catabasis Pharmaceuticals Inc. on CAT-1004 development. Catabasis Pharmaceuticals Press release. 2014. Available from: http://catabasis.com/pdfs/PPMD%20Catabasis%20Release%20-%20FINAL%20dec2014.pdf [Last accessed 24 June 2015]
   Google Scholar
• Catabasis Pharmaceuticals Initiates MoveDMD, a Phase 1/2 Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy. Catabasis Pharmaceuticals Press release. 2015. Available from: http://catabasis.com/pdfs/Catabasis%20FPI%20CAT-1004%20MoveDMD%20FINAL%20061715.pdf [Last accessed 24 June 2015]
   Google Scholar
• Heier CR, Damsker JM, Yu Q, et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med 2013;5:1569-85
   PubMed Web of Science ®Google Scholar
• Parent Project Muscular Dystrophy foundation and Foundation to Eradicate Duchenne award $1 million grant to ReveraGen BioPharma. ReveraGen BioPharma Press release. 2015. Available from: www.prnewswire.com/news-releases/parent-project-muscular-dystrophy-and-foundation-to-eradicate-duchenne-award-1-million-grant-to-reveragen-biopharma-300040653.html [Last accessed 23 June 2015]
   Google Scholar
• Halevy O, Genin O, Barzilai-Tutsch H, et al. Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone. Histol Histopathol 2013;28:211-26
   PubMed Web of Science ®Google Scholar
• Turgeman T, Hagai Y, Huebner K, et al. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone. Neuromuscul Disord 2008;18:857-68
   PubMed Web of Science ®Google Scholar
• Bodanovsky A, Guttman N, Barzilai-Tutsch H, et al. Halofuginone improves muscle-cell survival in muscular dystrophies. Biochim Biophys Acta 2014;1843:1339-47
   PubMed Web of Science ®Google Scholar
• Roffe S, Hagai Y, Pines M, et al. Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion. Exp Cell Res 2010;316:1061-9
   PubMed Web of Science ®Google Scholar
• Akashi therapeutics presents positive clinical data on HT-100 in patients with Duchenne muscular dystrophy. Akashi therapeutics press release. 2014. Available from: http://akashirx.com/news/positive-clinical-data/ [Last accessed 12 May 2015]
   Google Scholar
• Akashi Reports Positive Clinical Data on HT-100. Akashi Therapeutics press release. 2015. Available from: http://akashirx.com/2014site/wp-content/uploads/2015/06/Akashi_061815.pdf [Last accessed 23 June 2015]
   Google Scholar
• Vigh L, Literati PN, Horvath I, et al. Bimoclomol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects. Nat Med 1997;3:1150-4
   PubMed Web of Science ®Google Scholar
• Gehrig SM, van der Poel C, Sayer TA, et al. Hsp72 preserves muscle function and slows progression of severe muscular dystrophy. Nature 2012;484:394-8
   PubMed Web of Science ®Google Scholar
• Tinsley JM, Potter AC, Phelps SR, et al. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 1996;384:349-53
   PubMed Web of Science ®Google Scholar
• Tinsley J, Deconinck N, Fisher R, et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med 1998;4:1441-4
   PubMed Web of Science ®Google Scholar
• Tinsley JM, Fairclough RJ, Storer R, et al. Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS One 2011;6:e19189
   PubMed Web of Science ®Google Scholar
• Guiraud S, Squire SE, Edwards B, et al. Second-generation compound for the modulation of utrophin in the therapy of DMD. Hum Mol Genet 2015;24:4212-24
   PubMed Web of Science ®Google Scholar
• Summit reports preliminary results from phase 1b clinical trial of SMT C1100 FOR Duchenne muscular dystrophy. Summit Corporation plc press release. 2014. Available from: http://hsprod.investis.com/servlet/HsPublic?context=ir.access&ir_option=RNS_NEWS&ir_client_id=4747&item=1769298892685312 [Last accessed 28 July 2015]
   Google Scholar
• Spurney CF, Guerron AD, Yu Q, et al. Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. BMC Cardiovasc Disord 2011;11:20
   PubMed Web of Science ®Google Scholar
• Townsend D, Turner I, Yasuda S, et al. Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest 2010;120:1140-50
   PubMed Web of Science ®Google Scholar
• Yasuda S, Townsend D, Michele DE, et al. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005;436:1025-9
   PubMed Web of Science ®Google Scholar
• Ng R, Metzger JM, Claflin DR, et al. Poloxamer 188 reduces the contraction-induced force decline in lumbrical muscles from mdx mice. Am J Physiol Cell Physiol 2008;295:C146-50
   PubMed Web of Science ®Google Scholar
• Terry RL, Kaneb HM, Wells DJ. Poloxamer 188 has a deleterious effect on dystrophic skeletal muscle function. PLoS One 2014;9:e91221
   PubMed Web of Science ®Google Scholar
• Buyse GM, Van der Mieren G, Erb M, et al. Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. Eur Heart J 2009;30:116-24
   PubMed Web of Science ®Google Scholar
• Buyse GM, Goemans N, van den Hauwe M, et al. Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy. Pediatr Pulmonol 2013;48:912-20
   PubMed Web of Science ®Google Scholar
• Buyse GM, Goemans N, van den Hauwe M, et al. Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial. Neuromuscul Disord 2011;21:396-405
   PubMed Web of Science ®Google Scholar
• Buyse GM, Voit T, Schara U, et al. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet 2015;385:1748-57
   PubMed Web of Science ®Google Scholar
• Bordet T, Buisson B, Michaud M, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007;322:709-20
   PubMed Web of Science ®Google Scholar
• Bordet T, Berna P, Abitbol JL, et al. Olesoxime (TRO19622): A novel mitochondrial-targeted neuroprotective compound. Pharmaceuticals 2010;3:345-68
   Google Scholar
• Trophos announces top-line results of pivotal trial of olesoxime in spinal muscular atrophy Trophos Press release. 2014. Available from: www.trophos.com/news/pr20140310.htm [Last accessed 15 May 2015]
   Google Scholar
• Andreassi C, Angelozzi C, Tiziano FD, et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2004;12:59-65
   PubMed Web of Science ®Google Scholar
• Chang JG, Hsieh-Li HM, Jong YJ, et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001;98:9808-13
   PubMed Web of Science ®Google Scholar
• Darras BT, Kang PB. Clinical trials in spinal muscular atrophy. Curr Opin Pediatr 2007;19:675-9
   PubMed Web of Science ®Google Scholar
• Kernochan LE, Russo ML, Woodling NS, et al. The role of histone acetylation in SMN gene expression. Hum Mol Genet 2005;14:1171-82
   PubMed Web of Science ®Google Scholar
• Wirth B, Brichta L, Schrank B, et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet 2006;119:422-8
   PubMed Web of Science ®Google Scholar
• Mercuri E, Bertini E, Messina S, et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 2004;14:130-5
   PubMed Web of Science ®Google Scholar
• Brahe C, Vitali T, Tiziano FD, et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet 2005;13:256-9
   PubMed Web of Science ®Google Scholar
• Mercuri E, Bertini E, Messina S, et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 2007;68:51-5
   PubMed Web of Science ®Google Scholar
• Jarecki J, Chen X, Bernardino A, et al. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum Mol Genet 2005;14:2003-18
   PubMed Web of Science ®Google Scholar
• Singh J, Salcius M, Liu SW, et al. DcpS as a therapeutic target for spinal muscular atrophy. ACS Chem Biol 2008;3:711-22
   PubMed Web of Science ®Google Scholar
• Butchbach ME, Singh J, Thorsteinsdottir M, et al. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum Mol Genet 2010;19:454-67
   PubMed Web of Science ®Google Scholar
• Thurmond J, Butchbach ME, Palomo M, et al. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. J Med Chem 2008;51:449-69
   PubMed Web of Science ®Google Scholar
• Repligen reports positive results from Phase 1 clinical trial of RG3039 for Spinal muscular atrophy. RepliGen Corporation Press release. 2012. Available from: http://corporate.repligen.com/Cache/1500042021.PDF?Y=&O=PDF&D=&FID=1500042021&T=&IID=4325751 [Last accessed 23 June 2015]
   Google Scholar
• Gogliotti RG, Cardona H, Singh J, et al. The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum Mol Genet 2013;22:4084-101
   PubMed Web of Science ®Google Scholar
• Van Meerbeke JP, Gibbs RM, Plasterer HL, et al. The DcpS inhibitor RG3039 improves motor function in SMA mice. Hum Mol Genet 2013;22:4074-83
   PubMed Web of Science ®Google Scholar
• Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010;50:259-93
   PubMed Web of Science ®Google Scholar
• Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012;11:125-40
   PubMed Web of Science ®Google Scholar
• Hua Y, Vickers TA, Baker BF, et al. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol 2007;5:e73
   PubMed Web of Science ®Google Scholar
• Hua Y, Vickers TA, Okunola HL, et al. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 2008;82:834-48
   PubMed Web of Science ®Google Scholar
• Hua Y, Sahashi K, Hung G, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010;24:1634-44
   PubMed Web of Science ®Google Scholar
• Passini MA, Bu J, Richards AM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 2011;3:72ra18
   PubMed Web of Science ®Google Scholar
• Chiriboga C, Swoboda K, Darras B, et al. Results of an open-label, escalating dose study to assess the safety, tolerability, and dose range finding of a single intrathecal dose of ISIS-SMNRx in patients with spinal muscular atrophy (S36.002). Neurology 2013;80:S36-002
   Google Scholar
• Isis Pharmaceuticals Reports Data from ISIS-SMN Rx Phase 2 Study in Infants with Spinal Muscular Atrophy. Isis Pharmaceuticals Press release. 2015. Available from: www.prnewswire.com/news-releases/isis-pharmaceuticals-reports-data-from-isis-smn-rx-phase-2-study-in-infants-with-spinal-muscular-atrophy-300097480.html [Last accessed 24 June 2015]
   Google Scholar
• Isis Pharmaceuticals Reports Data from ISIS-SMN Rx in Children with Spinal Muscular Atrophy Isis Pharmaceuticals Press release. 2015. Available from: www.prnewswire.com/news-releases/isis-pharmaceuticals-reports-data-from-isis-smn-rx-in-children-with-spinal-muscular-atrophy-300102381.html [Last accessed 24 June 2015]
   Google Scholar
• Naryshkin NA, Weetall M, Dakka A, et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 2014;345:688-93
   PubMed Web of Science ®Google Scholar
• Spinal muscular atrophy program enters Phase 1b/2a trial in patients with SMA. PTC Therapeutics Press release. 2014. Available from: http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=883788 [Last accessed 15 May 2015]
   Google Scholar
• Update on Clinical Development of RG7800. CURE SMA Press release. 2015. Available from: www.curesma.org/news/clinical-development-rg7800.html [Last accessed 23 June 2015]
   Google Scholar
• Palacino J, Swalley SE, Song C, et al. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat Chem Biol 2015;11:511-17
   PubMed Web of Science ®Google Scholar
• Azzouz M, Le T, Ralph GS, et al. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest 2004;114:1726-31
   PubMed Web of Science ®Google Scholar
• Bevan AK, Duque S, Foust KD, et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther 2011;19:1971-80
   PubMed Web of Science ®Google Scholar
• Dayton RD, Wang DB and Klein RL. The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin Biol Ther 2012;12:757-66
   PubMed Web of Science ®Google Scholar
• Foust KD, Nurre E, Montgomery CL, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009;27:59-65
   PubMed Web of Science ®Google Scholar
• Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010;28:271-4
   PubMed Web of Science ®Google Scholar
• Passini MA, Bu J, Roskelley EM, et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 2010;120:1253-64
   PubMed Web of Science ®Google Scholar
• Bevan AK, Hutchinson KR, Foust KD, et al. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum Mol Genet 2010;19:3895-905
   PubMed Web of Science ®Google Scholar
• Dominguez E, Marais T, Chatauret N, et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 2011;20:681-93
   PubMed Web of Science ®Google Scholar
• AveXis Announces Dosing of First Patient in Intermediate Cohort in Gene Transfer Trial. AveXis Press release. 2014. Available from: http://avexisbio.com/avexis-announces-dosing-first-patient-intermediate-cohort-gene-transfer-trial/ [Last accessed 25 June 2015]
   Google Scholar
• AveXis Announces the Completion of Dosing of the Low Dose Cohort in US Clinical Trial for Spinal Muscular Atrophy. AveXis Press release. 2014. Available from: http://avexisbio.com/avexis-announces-completion-dosing-low-dose-cohort-us-clinical-trial-spinal-muscular-atrophy/ [Last accessed 25 June 2015]
   Google Scholar
• Benkhelifa-Ziyyat S, Besse A, Roda M, et al. Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther 2013;21:282-90
   PubMed Web of Science ®Google Scholar
• Meyer K, Ferraiuolo L, Schmelzer L, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA – a dose response study in mice and nonhuman primates. Molecular Therapy 2014;accepted article preview online 31 October 2014
   Google Scholar
• Passini MA, Bu J, Richards AM, et al. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther 2014;25:619-30
   PubMed Web of Science ®Google Scholar
• Corti S, Nizzardo M, Nardini M, et al. Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy. J Clin Invest 2008;118:3316-30
   PubMed Web of Science ®Google Scholar
• Corti S, Nizzardo M, Nardini M, et al. Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice. Brain 2010;133:465-81
   PubMed Web of Science ®Google Scholar
• Rossi SL, Nistor G, Wyatt T, et al. Histological and functional benefit following transplantation of motor neuron progenitors to the injured rat spinal cord. PLoS One 2010;5:e11852
   PubMed Web of Science ®Google Scholar
• Wyatt TJ, Rossi SL, Siegenthaler MM, et al. Human motor neuron progenitor transplantation leads to endogenous neuronal sparing in 3 models of motor neuron loss. Stem Cells Int 2011;2011:207230
   PubMed Web of Science ®Google Scholar
• Jay C, Nemunaitis G, Nemunaitis J, et al. Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2). Gene Regul Syst Bio 2008;2:243-52
   PubMedGoogle Scholar
• Nishikawa M, Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 2001;12:861-70
   PubMed Web of Science ®Google Scholar
• Phadke AP, Jay C, Chen SJ, et al. Safety and in vivo expression of a GNE-transgene: a novel treatment approach for hereditary inclusion body myopathy-2. Gene Regul Syst Bio 2009;3:89-101
   PubMedGoogle Scholar
• Nemunaitis G, Maples PB, Jay C, et al. Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy. J Gene Med 2010;12:403-12
   PubMed Web of Science ®Google Scholar
• Nemunaitis G, Jay CM, Maples PB, et al. Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex. Hum Gene Ther 2011;22:1331-41
   PubMed Web of Science ®Google Scholar
• Yonekawa T, Malicdan MC, Cho A, et al. Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice. Brain 2014;137:2670-9
   PubMed Web of Science ®Google Scholar
• Malicdan MC, Noguchi S, Hayashi YK, et al. Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model. Nat Med 2009;15:690-5
   PubMed Web of Science ®Google Scholar
• Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy. Ultragenyx Pharmaceutical Press release. 2015. Available from: http://ir.ultragenyx.com/releasedetail.cfm?ReleaseID=915288 [Last accessed 25 June 2015]
   Google Scholar
• Ultragenyx announces interim data from Phase 2 extension study of sialic acid extended-release at International Congress of the World Muscle Society. Ultragenyx pharmaceutical Press release. 2014. Available from: http://globenewswire.com/news-release/2014/10/13/672658/10102302/en/Ultragenyx-Announces-Interim-Data-From-Phase-2-Extension-Study-of-Sialic-Acid-Extended-Release-at-International-Congress-of-the-World-Muscle-Society.html [Last accessed 15 May 2015]
   Google Scholar
• Galeano B, Klootwijk R, Manoli I, et al. Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine. J Clin Invest 2007;117:1585-94
   PubMed Web of Science ®Google Scholar
• Shi Y, Fang M, Zhang M, et al. Method development and validation for the quantiation of ManNAc in human plasma using HILIC LC-MS/MS. American Society for Mass Spectrometry. Baltimore, MD: 2014
   Google Scholar
• Falk DJ, Todd AG, Lee S, et al. Peripheral nerve and neuromuscular junction pathology in Pompe disease. Hum Mol Genet 2014;24:625-36
   PubMed Web of Science ®Google Scholar
• ElMallah MK, Falk DJ, Lane MA, et al. Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9. Hum Gene Ther Methods 2012;23:148-56
   PubMed Web of Science ®Google Scholar
• Mah C, Cresawn KO, Fraites TJJr, et al. Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors. Gene Ther 2005;12:1405-9
   PubMed Web of Science ®Google Scholar
• Mah C, Pacak CA, Cresawn KO, et al. Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Mol Ther 2007;15:501-7
   PubMed Web of Science ®Google Scholar
• Mah CS, Falk DJ, Germain SA, et al. Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol Ther 2010;18:502-10
   PubMed Web of Science ®Google Scholar
• Han SO, Li S, Brooks ED, et al. Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade. Hum Gene Ther 2015;26:26-35
   PubMed Web of Science ®Google Scholar
• Elmallah MK, Falk DJ, Nayak S, et al. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in Pompe mice. Mol Ther 2014;22:702-12
   PubMed Web of Science ®Google Scholar
• Qiu K, Falk DJ, Reier PJ, et al. Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice. Mol Ther 2012;20:21-7
   PubMed Web of Science ®Google Scholar
• Sun B, Zhang H, Franco LM, et al. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. Mol Ther 2005;11:889-98
   PubMed Web of Science ®Google Scholar
• Sun B, Zhang H, Franco LM, et al. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol Ther 2005;11:57-65
   PubMed Web of Science ®Google Scholar
• Fraites TJJr, Schleissing MR, Shanely RA, et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 2002;5:571-8
   PubMed Web of Science ®Google Scholar
• Conlon TJ, Erger K, Porvasnik S, et al. Preclinical toxicology and biodistribution studies of recombinant adeno-associated virus 1 human acid alpha-glucosidase. Hum Gene Ther Clin Dev 2013;24:127-33
   PubMed Web of Science ®Google Scholar
• Safety study of recombinant Adeno-associated virus acid alpha-glucosidase to treat Pompe disease. University of Florida Clinical trial. 2009. Available from: https://clinicaltrials.gov/ct2/show/NCT00976352?term=AAV+Pompe&rank=2 [Last accessed 15 May 2015]
   Google Scholar
• Smith BK, Collins SW, Conlon TJ, et al. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther 2013;24:630-40
   PubMed Web of Science ®Google Scholar
• Re-administration of intramusclar AAV9 in patients with late-onset Pompe disease (AAV9-GAA IM). University of Florida Clinical trial. 2014. Available from: https://clinicaltrials.gov/ct2/show/NCT02240407?term=AAV+Pompe&rank=1 [Last accessed 15 May 2015]
   Google Scholar
• Zhu Y, Jiang JL, Gumlaw NK, et al. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther 2009;17:954-63
   PubMed Web of Science ®Google Scholar
• Zhu Y, Li X, McVie-Wylie A, et al. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Biochem J 2005;389:619-28
   PubMed Web of Science ®Google Scholar
• Safety and efficacy evaluation of repeat neoGAA dosing in late onset Pompe disease patients. Genzyme Sanofi Clinical trial, July 2. 2013. Available from: https://clinicaltrials.gov/ct2/show/record/NCT01898364?term=neoGAA&rank=1 [Last accessed 15 May 2015]
   Google Scholar
• NeoGAA extension study (NEO-EXT). Genzyme Sanofi Clinical trial, December 4. 2013. Available from: https://clinicaltrials.gov/ct2/show/NCT02032524?term=neoGAA&rank=2 [Last accessed 15 May 2015]
   Google Scholar
• Koeberl DD, Luo X, Sun B, et al. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Mol Genet Metab 2011;103:107-12
   PubMed Web of Science ®Google Scholar
• Farah BL, Madden L, Li S, et al. Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid alpha-glucosidase uptake in the limb muscles of mice with Pompe disease. FASEB J 2014;28:2272-80
   PubMed Web of Science ®Google Scholar
• Koeberl DD, Li S, Dai J, et al. β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Mol Genet Metab 2012;105:221-7
   PubMed Web of Science ®Google Scholar
• Li S, Sun B, Nilsson MI, et al. Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease. FASEB J 2013;27:34-44
   PubMed Web of Science ®Google Scholar
• Gregorevic P, Ryall JG, Plant DR, et al. Chronic β-agonist administration affects cardiac function of adult but not old rats, independent of β -adrenoceptor density. Am J Physiol Heart Circ Physiol 2005;289:H344-9
   PubMed Web of Science ®Google Scholar
• Ryall JG, Schertzer JD, Alabakis TM, et al. Intramuscular β2-agonist administration enhances early regeneration and functional repair in rat skeletal muscle after myotoxic injury. J Appl Physiol 2008;105:165-72
   PubMed Web of Science ®Google Scholar
• LeBowitz JH, Grubb JH, Maga JA, et al. Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice. Proc Natl Acad Sci USA 2004;101:3083-8
   PubMed Web of Science ®Google Scholar
• Safety/tolerability/pharmacokinetic (PK)/pharmacodynamics (PD) study of BMN701 in patients with late-onset Pompe disease. BioMarin Pharmaceutical Clinical trial, October 27. 2010. Available from: https://clinicaltrials.gov/ct2/show/NCT01230801?term=BMN+701&rank=1 [Last accessed 15 May 2015]
   Google Scholar
• BioMarin to advance BMN-701 for Pompe disease to next phase of development. BioMarin Press release, March 19. 2013. Available from: http://investors.bmrn.com/releasedetail.cfm?ReleaseID=749572 [Last accessed 23 June 2015]
   Google Scholar
• BMN 701 Phase 3 in rhGAA exposed patients with late onset Pompe disease (INSPIRE study). BioMarin Pharmaceutical Clinical trial, August 13. 2013. Available from: https://clinicaltrials.gov/ct2/show/NCT01924845?term=pompe+inspire&rank=1 [Last accessed 15 May 2015]
   Google Scholar
• Grounds MD, Radley HG, Lynch GS, et al. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis 2008;31:1-19
   PubMed Web of Science ®Google Scholar
• Radley HG, De Luca A, Lynch GS, et al. Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions. Int J Biochem Cell Biol 2007;39:469-77
   PubMed Web of Science ®Google Scholar
• Available from: www.treat-nmd.eu/research/preclinical/dmd-sops/
   Google Scholar
• Zatz M, Betti RT, Frota-Pessoa O. Treatment of Duchenne muscular dystrophy with growth hormone inhibitors. Am J Med Genet 1986;24:549-66
   PubMed Web of Science ®Google Scholar
• Coakley JH, Moorcraft J, Hipkin LJ, et al. The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 1988;51:1551-7
   PubMed Web of Science ®Google Scholar
• Zatz M, Rapaport D, Vainzof M, et al. Effect of mazindol on growth hormone levels in patients with Duchenne muscular dystrophy. Am J Med Genet 1988;31:821-33
   PubMed Web of Science ®Google Scholar
• Sharp PS, Bye-a-Jee H, Wells DJ. Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Mol Ther 2011;19:165-71
   PubMed Web of Science ®Google Scholar
• BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping. BioMarin press release, April 27. 2015. Available from: http://investors.bmrn.com/releasedetail.cfm?ReleaseID=908731 [Last accessed 15 May 2015]
   Google Scholar
• BioMarin Submits Drisapersen MAA to EMA for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping. BioMarin press release, June 8. 2015. Available from: http://investors.bmrn.com/releasedetail.cfm?ReleaseID=916857 [Last accessed 15 June 2015]
   Google Scholar
• Flanigan KM, Voit T, Rosales XQ, et al. Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial. Neuromuscul Disord 2014;24:16-24
   PubMed Web of Science ®Google Scholar
• Voit T, Topaloglu H, Straub V, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 2014;13:987-96
   PubMed Web of Science ®Google Scholar
• Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447:87-91
   PubMed Web of Science ®Google Scholar
• Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 2014;50:477-87
   PubMed Web of Science ®Google Scholar
• Finkel RS, Flanigan KM, Wong B, et al. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS One 2013;8:e81302
   PubMed Web of Science ®Google Scholar
• Haas M, Vlcek V, Balabanov P, et al. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. Neuromuscul Disord 2015;25:5-13
   PubMed Web of Science ®Google Scholar
• Aoki Y, Nakamura A, Yokota T, et al. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther 2010;18:1995-2005
   PubMed Web of Science ®Google Scholar
• Sarepta Therapeutics Reports Long-Term Outcomes through 144 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy. Sarepta Therapeutics press release, July 10. 2014. Available from: www.mda.org/media/press-releases/sarepta-therapeutics-reports-long-term-outcomes-through-144-weeks-phase-iib [Last accessed 15 May 2015]
   Google Scholar
• Goyenvalle A, Babbs A, Powell D, et al. Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. Mol Ther 2010;18:198-205
   PubMed Web of Science ®Google Scholar
• Initial Efficacy and Safety Evaluation in Cynomolgus Monkeys of AVI-5038, a Peptide Conjugated Phosphorodiamidate Morpholino Oligomer (PPMO) Being Developed To Skip Exon 50 in Duchenne Muscular Dystrophy. April 14. 2010. Available from: http://community.parentprojectmd.org/forum/topics/ppmo-skipping-exon-50-results
   Google Scholar
• Martin PT, Xu R, Rodino-Klapac LR, et al. Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice. Am J Physiol Cell Physiol 2009;296:C476-88
   PubMed Web of Science ®Google Scholar
• Chicoine LG, Rodino-Klapac LR, Shao G, et al. Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin alpha2 surrogates. Mol Ther 2014;22:713-24
   PubMed Web of Science ®Google Scholar
• Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy. Pfizer Inc. press release, December 17. 2014. Available from: www.pfizer.com/news/press-release/press-release-detail/pfizer_initiates_phase_2_study_of_pf_06252616_in_duchenne_muscular_dystrophy [Last accessed 15 May 2015]
   Google Scholar
• Akashi Therapeutics Presents Positive Clinical Data on HT-100 in Patients with Duchenne Muscular Dystrophy. Akashi Therapeutics press release, July 3. 2014. Available from: http://akashirx.com/news/positive-clinical-data/ [Last accessed 15 May 2015]
   Google Scholar
• Anderson JE, McIntosh LM, Poettcker R. Deflazacort but not prednisone improves both muscle repair and fiber growth in diaphragm and limb muscle in vivo in the mdx dystrophic mouse. Muscle Nerve 1996;19:1576-85
   PubMed Web of Science ®Google Scholar
• Biggar WD, Harris VA, Eliasoph L, et al. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249-55
   PubMed Web of Science ®Google Scholar
• Milne J, Donovan J, Sweeney HL, et al. CAT-1004, a novel anti-inflammatory agent under development for treatment of Duchenne muscular dystrophy. Neuromuscul Disord 2014;24:825
   Web of Science ®Google Scholar
• Uaesoontrachoon K, Quinn JL, Tatem KS, et al. Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Hum Mol Genet 2014;23:3239-49
   PubMed Web of Science ®Google Scholar
• Rooney JE, Gurpur PB, Burkin DJ. Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy. Proc Natl Acad Sci USA 2009;106:7991-6
   PubMed Web of Science ®Google Scholar
• Tinsley J, Muntoni F, Spinty S, et al. Utrophin modulators to treat Duchenne muscular dystrophy (DMD): Phase 1b Clinical Trial Results of SMT C1100 (P2.006). Neurology 2015;84:Supp. P2-006
   Google Scholar
• Gallet R, Tseliou E, Dawkins J, et al. Intracoronary delivery of self-assembling heart-derived microtissues (cardiospheres) for prevention of adverse remodeling in a pig model of convalescent myocardial infarction. Circ Cardiovasc Interv 2015;8
   Web of Science ®Google Scholar
• Capricor Announces Receipt of FDA Clearance for the Phase I/II Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Related Cardiomyopathy. Capricor Therapeutics. Available from: www.irdirect.net/pr/release/id/1339225 [Last accessed 15 June 2015]
   Google Scholar
• Vasquez I, Tan N, Boonyasampant M, et al. Partial opening and subconductance gating of mechanosensitive ion channels in dystrophic skeletal muscle. J Physiol 2012;590:6167-85
   PubMed Web of Science ®Google Scholar
• GsMTx4: Therapy for Muscular Dystrophy by inhibition of mechanosensitive ion channels. TREAT-NMD TACT review, January 15. 2011. Available from: www.treat-nmd.eu/resources/tact/reviews/past/gsmtx4/ [Last accessed 17 July 2015]
   Google Scholar
• EspeRare’s Rimeporide receives Orphan Drug Designation in Duchenne Muscular Dystrophy. EspeRare press release, May 4. 2015. Available from: http://esperare.org/en/news/esperares-investigational-compoud-rimeporide-receives-orphan-drug-designation-duchenne-muscular [Last accessed 15 May 2015]
   Google Scholar
• De Arcangelis V, Strimpakos G, Gabanella F, et al. Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy. J Cell Physiol 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Martin EA, Barresi R, Byrne BJ, et al. Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci Transl Med 2012;4:162ra55
   Web of Science ®Google Scholar
• Nelson MD, Rader F, Tang X, et al. PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. Neurology 2014;82:2085-91
   PubMed Web of Science ®Google Scholar
• Niethamer TK, Yardeni T, Leoyklang P, et al. Oral monosaccharide therapies to reverse renal and muscle hyposialylation in a mouse model of GNE myopathy. Mol Genet Metab 2012;107:748-55
   PubMed Web of Science ®Google Scholar
• DEX-M74 for GNE Myopathy (Hereditary Inclusion Body Myopathy). National Institutes of Health Therapeutics for Rare and Neglected Diseases (TRND) update, June 1. 2015. Available from: http://ncats.nih.gov/trnd/projects/active/dex-m74-gne-myopathy [Last accessed 23 July 2015]
   Google Scholar
• Yorke SC. N-Acetylmannosamine and Mammalian Cell Culture Production of Recombinant Therapeutic Human Glycoproteins. Chemistry in New Zealand 2013 2014;77:18
   Google Scholar
• Case LE, Bjartmar C, Morgan C, et al. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease. Neuromuscul Disord 2015;25:321-32
   PubMed Web of Science ®Google Scholar
• Clayton NP, Nelson CA, Weeden T, et al. Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease. Mol Ther Nucleic Acids 2014;3:e206
   PubMedGoogle Scholar
• Update from Genzyme on neoGAA Pompe clinical development program 11th February 2014 Canadian association of Pompe update March 3. 2014. Available from: www.pompecanada.com/news/50-research-a-studies/103-update-from-genzyme-on-neogaa-pompe-clinical-development-program-11th-february-2014 [Last accessed 15 May 2015]
   Google Scholar
• Khanna R, Flanagan JJ, Feng J, et al. The pharmacological chaperone AT2220 increases recombinant human acid alpha-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PLoS One 2012;7:e40776
   PubMed Web of Science ®Google Scholar
• Khanna R, Powe ACJr, Lun Y, et al. The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease. PLoS One 2014;9:e102092
   PubMed Web of Science ®Google Scholar
• Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease. Amicus Therapeutics press release, February 27. 2009. Available from: www.fiercebiotech.com/press-releases/amicus-therapeutics-suspends-enrollment-phase-2-clinical-trial-at2220-pompe-disease-0 [Last accessed 15 May 2015]
   Google Scholar
• Maga JA, Zhou J, Kambampati R, et al. Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in pompe mice. J Biol Chem 2013;288:1428-38
   PubMed Web of Science ®Google Scholar
• Rigo F, Chun SJ, Norris DA, et al. Pharmacology of a central nervous system delivered 2’-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J Pharmacol Exp Ther 2014;350:46-55
   PubMed Web of Science ®Google Scholar
• Monani UR, De Vivo DC. Neurodegeneration in spinal muscular atrophy: from disease phenotype and animal models to therapeutic strategies and beyond. Future Neurol 2014;9:49-65
   PubMedGoogle Scholar
• Kaczmarek A, Schneider S, Wirth B, et al. Investigational therapies for the treatment of spinal muscular atrophy. Expert Opin Investig Drugs 2015;24:867-81
   PubMed Web of Science ®Google Scholar
• Sunyach C, Michaud M, Arnoux T, et al. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model. Neuropharmacology 2012;62:2346-52
   PubMed Web of Science ®Google Scholar